Tresiba® (insulin degludec) (NN1250)

:Type 1 and 2 diabetes
:Filed for registration

A new-generation basal insulin with an ultra-long duration of action of more than 42 hours. Approved to offer patients reduced risk of hypoglycaemia and the possibility of adjusting the time of injection, when needed. Approved and launched in the EU, Japan and other markets. Additional data required by the US FDA are being generated for the planned resubmission.

Company announcements
Increased operating profit in local currencies by 11% in the first nine months of 2014 (30 Oct 2014)
Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014 (07 Aug 2014)
Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities (25 Jul 2014)
Read more company announcements

Press releases
Tresiba® receives positive opinion from CHMP for treatment of children with diabetes (19 Dec 2014)
New Xultophy® (IDegLira) data show rapid and predictable glycaemic improvements in people with type 2 diabetes (19 Sep 2014)
Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen (18 Sep 2014)
Read more press releases

Scientific abstracts

No scientific abstracts matching the search criteria


You can search for more clinical trials on http://clinicaltrials.gov
  •